Decompensated heart failure: is there a role for the outpatient use of nesiritide?

Clyde W. Yancy, John C Jr. Burnett, Gregg C. Fonarow, Marc A. Silver

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Heart failure (HF) management has seen enormous advances in the past two decades, including publication of HF management guidelines targeted at further reduction of morbidity and mortality. Nonetheless, the morbidity of HF has steadily increased and now represents one of the largest health care expenditures in this country. Because hospitalization for HF is most likely for patients with more advanced HF, they share a disproportionate burden of the hospitalization costs and will require treatment regimens beyond the current guidelines, if this burden is to be alleviated. In June 2004, a group of investigators who helped establish the natriuretic peptide treatment paradigm, met to discuss the potential role of nesiritide as an outpatient treatment option for patients with symptomatic HF who were at high risk for repeated admissions, a syndrome now described as "chronic decompensated HF." This report presents their considerations on the contribution of natriuretic peptide physiology to the amelioration of progressive left ventricular dysfunction, the therapeutic use of B-type natriuretic peptide, and its potential application to the outpatient management of acute and chronic decompensated HF. The use of outpatient IV nesiritide was considered a promising treatment option for symptomatic chronic decompensated HF patients that merits further investigation. Such an approach, once validated, should be integrated into an evidence-based HF disease management program.

Original languageEnglish (US)
Pages (from-to)230-236
Number of pages7
JournalCongestive heart failure (Greenwich, Conn.)
Volume10
Issue number5
StatePublished - Sep 2004
Externally publishedYes

Fingerprint

Brain Natriuretic Peptide
Outpatients
Heart Failure
Natriuretic Peptides
Hospitalization
Guidelines
Morbidity
Left Ventricular Dysfunction
Therapeutic Uses
Therapeutics
Disease Management
Health Expenditures
Publications
Heart Diseases
Research Personnel
Delivery of Health Care
Costs and Cost Analysis
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Decompensated heart failure : is there a role for the outpatient use of nesiritide? / Yancy, Clyde W.; Burnett, John C Jr.; Fonarow, Gregg C.; Silver, Marc A.

In: Congestive heart failure (Greenwich, Conn.), Vol. 10, No. 5, 09.2004, p. 230-236.

Research output: Contribution to journalArticle

Yancy, Clyde W. ; Burnett, John C Jr. ; Fonarow, Gregg C. ; Silver, Marc A. / Decompensated heart failure : is there a role for the outpatient use of nesiritide?. In: Congestive heart failure (Greenwich, Conn.). 2004 ; Vol. 10, No. 5. pp. 230-236.
@article{f4f26193b9404f77845827cfb49f5377,
title = "Decompensated heart failure: is there a role for the outpatient use of nesiritide?",
abstract = "Heart failure (HF) management has seen enormous advances in the past two decades, including publication of HF management guidelines targeted at further reduction of morbidity and mortality. Nonetheless, the morbidity of HF has steadily increased and now represents one of the largest health care expenditures in this country. Because hospitalization for HF is most likely for patients with more advanced HF, they share a disproportionate burden of the hospitalization costs and will require treatment regimens beyond the current guidelines, if this burden is to be alleviated. In June 2004, a group of investigators who helped establish the natriuretic peptide treatment paradigm, met to discuss the potential role of nesiritide as an outpatient treatment option for patients with symptomatic HF who were at high risk for repeated admissions, a syndrome now described as {"}chronic decompensated HF.{"} This report presents their considerations on the contribution of natriuretic peptide physiology to the amelioration of progressive left ventricular dysfunction, the therapeutic use of B-type natriuretic peptide, and its potential application to the outpatient management of acute and chronic decompensated HF. The use of outpatient IV nesiritide was considered a promising treatment option for symptomatic chronic decompensated HF patients that merits further investigation. Such an approach, once validated, should be integrated into an evidence-based HF disease management program.",
author = "Yancy, {Clyde W.} and Burnett, {John C Jr.} and Fonarow, {Gregg C.} and Silver, {Marc A.}",
year = "2004",
month = "9",
language = "English (US)",
volume = "10",
pages = "230--236",
journal = "Prevention and Management of Congestive Heart Failure",
issn = "1079-7998",
publisher = "Le Jacq Communications, Inc.",
number = "5",

}

TY - JOUR

T1 - Decompensated heart failure

T2 - is there a role for the outpatient use of nesiritide?

AU - Yancy, Clyde W.

AU - Burnett, John C Jr.

AU - Fonarow, Gregg C.

AU - Silver, Marc A.

PY - 2004/9

Y1 - 2004/9

N2 - Heart failure (HF) management has seen enormous advances in the past two decades, including publication of HF management guidelines targeted at further reduction of morbidity and mortality. Nonetheless, the morbidity of HF has steadily increased and now represents one of the largest health care expenditures in this country. Because hospitalization for HF is most likely for patients with more advanced HF, they share a disproportionate burden of the hospitalization costs and will require treatment regimens beyond the current guidelines, if this burden is to be alleviated. In June 2004, a group of investigators who helped establish the natriuretic peptide treatment paradigm, met to discuss the potential role of nesiritide as an outpatient treatment option for patients with symptomatic HF who were at high risk for repeated admissions, a syndrome now described as "chronic decompensated HF." This report presents their considerations on the contribution of natriuretic peptide physiology to the amelioration of progressive left ventricular dysfunction, the therapeutic use of B-type natriuretic peptide, and its potential application to the outpatient management of acute and chronic decompensated HF. The use of outpatient IV nesiritide was considered a promising treatment option for symptomatic chronic decompensated HF patients that merits further investigation. Such an approach, once validated, should be integrated into an evidence-based HF disease management program.

AB - Heart failure (HF) management has seen enormous advances in the past two decades, including publication of HF management guidelines targeted at further reduction of morbidity and mortality. Nonetheless, the morbidity of HF has steadily increased and now represents one of the largest health care expenditures in this country. Because hospitalization for HF is most likely for patients with more advanced HF, they share a disproportionate burden of the hospitalization costs and will require treatment regimens beyond the current guidelines, if this burden is to be alleviated. In June 2004, a group of investigators who helped establish the natriuretic peptide treatment paradigm, met to discuss the potential role of nesiritide as an outpatient treatment option for patients with symptomatic HF who were at high risk for repeated admissions, a syndrome now described as "chronic decompensated HF." This report presents their considerations on the contribution of natriuretic peptide physiology to the amelioration of progressive left ventricular dysfunction, the therapeutic use of B-type natriuretic peptide, and its potential application to the outpatient management of acute and chronic decompensated HF. The use of outpatient IV nesiritide was considered a promising treatment option for symptomatic chronic decompensated HF patients that merits further investigation. Such an approach, once validated, should be integrated into an evidence-based HF disease management program.

UR - http://www.scopus.com/inward/record.url?scp=12144262165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144262165&partnerID=8YFLogxK

M3 - Article

C2 - 15470300

AN - SCOPUS:12144262165

VL - 10

SP - 230

EP - 236

JO - Prevention and Management of Congestive Heart Failure

JF - Prevention and Management of Congestive Heart Failure

SN - 1079-7998

IS - 5

ER -